Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study

By afschroeder • July 25, 2026

Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Zhang Q, Tsurutani J, Kalinsky K, Rubini Liedke PE, Nowecki Z, Tolaney SM, Zhao K, Atuah K, Verma D, Xu B, Bardia A; TROPION-Breast01 investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 study. ESMO Open. 2026 Jul 24;11(8):108330. doi: 10.1016/j.esmoop.2026.108330. Epub ahead of print. PMID: 42497483.

Tags: Dato-DXd, Datopotamab deruxtecan, Hematology/Oncology, HR+/HER2– breast cancer, patient-reported outcomes, Publications, safety, TROPION-Breast01

The Role of Immunotherapy in Breast Cancer and Mechanisms of Immune Escape: What Surgeons Need to Know

Graham DM, Lofftus S, Azizi L, Berkowitz MJ, Teshome M. The Role of Immunotherapy in Breast Cancer and Mechanisms of Immune Escape: What Surgeons Need[...]

Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial

Wainberg ZA, Lee KW, Kim JG, Devoe C, Strickler JH, Baum J, Jia C, Kagey MH, Sirard CA, Stein A, Scott AJ, Pelster M, Moehler[...]

Neuroendocrine Tumor of the Breast in a Young Woman With MEN2A Syndrome

Vaghashia D, Sullivan P, Livhits MJ, Donangelo I, Laklouk I, Teshome M, Lipsyc-Sharf M. Neuroendocrine Tumor of the Breast in a Young Woman With MEN2A[...]